Apollo Hospitals Targets ₹25,000-Crore Revenue for HealthCo Ahead of FY27 IPO

pitals Enterprise Ltd is accelerating its omnichannel healthcare platform, Apollo HealthCo, toward a ₹25,000-crore annual revenue run-rate with 6–7% EBITDA margins by FY27-end—paving the way for a high-profile public listing in Q4FY27, senior executives revealed to Moneycontrol. The subsidiary, backed by global private equity giant Advent International, has engineered a sharp financial turnaround, reporting a fourfold surge in profit after tax (PAT) to ₹73.4 crore in Q2FY26. Cash losses narrowed significantly to ₹38.6 crore from ₹85 crore a year earlier, signaling disciplined cost control and operational momentum. Strategic Convergence of Offline, Digital, and Distribution Apollo HealthCo integrates three high-growth pillars: Offline pharmacy and distribution (via Apollo Pharmacies), Digital health services through the Apollo 24/7 platform, Wholesale drug distribution via Keimed, which is in the final stages of merger.